Lawrence P. Guiheen

Board Director

Director

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 1 saleJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€367k

Latest filing published 17 Mar 2026 for Adma Biologics, INC., €95k. Read the official filing

Filing timeline

BuySale

Lawrence P. Guiheen

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Lawrence P. Guiheen: trading record in brief

This profile gathers the share dealings of Lawrence P. Guiheen in Adma Biologics, Inc., where the filings describe the role as board member. We count 11 filings; the first trade dates from 7 March 2022 and the latest from 17 March 2026.

Sales make up the whole of the open-market record (1 sale, €367k). Besides market trades, the filings include 5 share grants and 3 option exercises.

The newest entry dates from 17 March 2026: a transaction, in Adma Biologics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.